Skip to Content
Missouri & Illinois Personal Injury Attorneys 800-391-4318
Top

Invokana Warnings Continue to Increase

|

The Food and Drug Administration has issued additional warnings regarding the use of prescription drug Invokana. The canagliflozin, Invokana, is prescribed to treat Type 2 diabetes and was approved by the FDA in 2013. The medication is prescribed by physicians to lower the blood sugar levels in individuals that suffer from Type 2 diabetes. In May, the FDA issued a warning to users that Invokana could cause dangerous amounts of toxic acids in the bloodstream, also known as Ketoacidosis, that can cause serious injuries and death. Most recently, the FDA has released yet another Invokana warning indicating the medication can reduce the bone mineral density in users that could lead to bone fractures. Several users are now claiming that Invokana’s manufacturers, Johnson and Johnson, have failed to issue effective warnings to physicians and patients regarding the dangerous side effects of the drug.

Millions of individuals are required to take prescription medication to prevent or treat illnesses and ailments. Unfortunately, some dangerous drugs have caused more injuries than improvements for users, and the manufacturers are often to blame. When a manufacturer fails to warn consumers regarding the potential dangers and side effects of their drug, they may be held responsible for the injuries incurred. If you have sustained in injury, illness, or lost a loved one due to a dangerous drug, you may have grounds to recover compensation for your damages.

The experienced St. Louis product liability attorneys at Meyerkord & Kurth, LLC have the experience and skills necessary to handle your case. Our attorneys will work diligently to hold the negligent drug manufacturer accountable for your damages. We will fight to recover the maximum compensation for your medical bills, funeral expenses, loss of economic support, and emotional damages. Contact us to receive a free no-obligation consultation.

Categories: 
Share To: